Paired box 3-Forkhead box O1 fusion protein (PAX3-FOXO1) (PAX3-FOXO1)

The Paired box 3-Forkhead box O1 (PAX3-FOXO1) fusion protein is a chimeric transcription factor that serves as the pathognomonic driver for alveolar rhabdomyosarcoma (ARMS), an aggressive pediatric soft tissue cancer (National Cancer Institute). It is generated by a t(2;13)(q35;q14) chromosomal translocation that fuses the DNA-binding domains of PAX3 with the powerful transactivation domain of FOXO1 (PubMed: 25154350). This fusion protein functions as a master regulator, hijacking the myogenic program to promote uncontrolled cell proliferation, inhibit apoptosis, and prevent terminal muscle differentiation (PubMed: 28343171). PAX3-FOXO1 exerts its effects by recruiting epigenetic co-activators like BRD4 and p300 to super-enhancers, creating a massive transcriptional output of oncogenes such as MYCN and FGFR4 (PubMed: 24632557). Although it is considered a difficult "undruggable" target due to its lack of enzymatic pockets, therapeutic strategies currently focus on disrupting its transcriptional complex using HDAC inhibitors like Entinostat or BET bromodomain inhibitors (PubMed: 30212333). Identifying the PAX3-FOXO1 fusion via FISH or RT-PCR is critical for the diagnosis and risk stratification of rhabdomyosarcoma patients.

Other names

PAX3-FKHRt(2;13)(q35;q14) fusion proteinPaired box 3-Forkhead box protein O1 fusion

Inhibition of the PAX3-FOXO1 transcriptional complex through disruption of epigenetic co-regulator recruitment (e.g., BRD4, HDACs) or direct DNA-binding interference (PubMed: 28343171, 24632557).